

1 **The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins,**  
2 **diversified for accessory proteins and stable long-term in children**

3  
4 Asmaa Hachim<sup>1</sup>, Haogao Gu<sup>2</sup>, Otared Kavian<sup>3</sup>, Mike YW Kwan<sup>4</sup>, Wai-hung Chan<sup>5</sup>, Yat  
5 Sun Yau<sup>5</sup>, Susan S Chiu<sup>6</sup>, Owen TY Tsang<sup>7</sup>, David SC Hui<sup>8</sup>, Fionn Ma<sup>1</sup>, Eric HY Lau<sup>9</sup>,  
6 Samuel MS Cheng<sup>2</sup>, Leo LM Poon<sup>1, 2</sup>, JS Malik Peiris<sup>1, 2</sup>, Sophie A Valkenburg<sup>1\*^</sup> and  
7 Niloufar Kavian<sup>1, 10,11\*</sup>.

8  
9 **Affiliation**

10 <sup>1</sup>HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of  
11 Hong Kong, Hong Kong SAR, China.

12 <sup>2</sup>Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine,  
13 The University of Hong Kong, Hong Kong SAR, China.

14 <sup>3</sup>Department of Mathematics, Université de Versailles Saint-Quentin, Versailles, France

15 <sup>4</sup>Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Hospital Authority of Hong  
16 Kong, Special Administrative Region of Hong Kong, China.

17 <sup>5</sup>Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special  
18 Administrative Region of Hong Kong, China.

19 <sup>6</sup>Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary  
20 Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.

21 <sup>7</sup>Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special  
22 Administrative Region of Hong Kong, China.

23 <sup>8</sup>Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong,  
24 Hong Kong SAR, China.

25 <sup>9</sup>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li  
26 Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

27 <sup>10</sup>Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de  
28 Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d’Immunologie  
29 Biologique, Paris, France.

30 <sup>11</sup>Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

31

32 \*Contributed equally to this study

33

34 ^corresponding author:

35 Sophie A Valkenburg

36 HKU Pasteur Research Pole

37 School of Public Health

38 The University of Hong Kong

39 [sophie.v@hku.hk](mailto:sophie.v@hku.hk)

40

41 Short title: COVID-19 antibodies in children

42

43 **Keywords:** Antibody, COVID-19, asymptomatic, pediatric, IFN, accessory, structural,  
44 longitudinal

45

46 **Author contributions**

47 A.H. and N.K. performed the experiments and analysed the data. H.G., O.K. and E.H.Y.L  
48 performed specialist statistical analysis. M.Y.W.K, W.H.C, Y.S.Y, S.S.C, O.T.Y.T,  
49 D.S.C.H and S.M.S.C provided clinical samples, which F.M processed. A.H., L.L.M.P.,

50 J.S.M.P., S.A.V. and N.K. designed the study, interpreted results and wrote the  
51 manuscript.

52

53 **Abstract**

54 **Background:** Children are less clinically affected by SARS-CoV-2 infection than adults  
55 with the majority of cases being mild or asymptomatic and the differences in infection  
56 outcomes are poorly understood. The kinetics, magnitude and landscape of the antibody  
57 response may impact the clinical severity and serological diagnosis of COVID-19. Thus,  
58 a comprehensive investigation of the antibody landscape in children and adults is needed.

59 **Methods:** We tested 254 plasma from 122 children with symptomatic and asymptomatic  
60 SARS-CoV-2 infections in Hong Kong up to 206 days post symptom onset, including 146  
61 longitudinal samples from 58 children. Adult COVID-19 patients and pre-pandemic  
62 controls were included for comparison. We assessed antibodies to a 14-wide panel of  
63 SARS-CoV-2 structural and accessory proteins by Luciferase Immunoprecipitation  
64 System (LIPS).

65 **Findings:** Children have lower levels of Spike and Nucleocapsid antibodies than adults,  
66 and their cumulative humoral response is more expanded to accessory proteins (NSP1  
67 and Open Reading Frames (ORFs)). Sensitive serology using the three N, ORF3b, ORF8  
68 antibodies can discriminate COVID-19 in children. Principal component analysis revealed  
69 distinct serological signatures in children and the highest contribution to variance were  
70 responses to non-structural proteins ORF3b, NSP1, ORF7a and ORF8. Longitudinal  
71 sampling revealed maintenance or increase of antibodies for at least 6 months, except  
72 for ORF7b antibodies which showed decline. It was interesting to note that children have  
73 higher antibody responses towards known IFN antagonists: ORF3b, ORF6 and ORF7a.  
74 The diversified SARS-CoV-2 antibody response in children may be an important factor in  
75 driving control of SARS-CoV-2 infection.

## 76 **Introduction**

77 The SARS-CoV-2 virus emerged in December 2019 and given the lack of pre-existing  
78 immunity has caused a pandemic. The spectrum of COVID-19 disease ranges from  
79 asymptomatic to lethal infection. It is now evident that the immune response plays a major  
80 role in the pathogenicity and outcome COVID-19<sup>1</sup>. Children are minimally affected  
81 clinically by SARS-CoV-2 and the morbidity and mortality observed in adults increases  
82 progressively with age, although the viral loads in the respiratory tract are reportedly  
83 comparable between children of all ages and adults<sup>2</sup>. The multisystem inflammatory  
84 syndrome (MIS-C) that appears in children after infection with SARS-CoV-2 is a rare  
85 exception (0.002% of cases) to the generally milder clinical disease observed<sup>3</sup>.  
86 Symptoms such as fever, cough, pneumonia and elevated C-reactive protein which are  
87 associated with disease severity, are less common in children<sup>4</sup>. The majority of children  
88 are asymptomatic and only a minority develop mild symptoms (most commonly fever,  
89 cough, pharyngitis, gastrointestinal symptoms and anosmia)<sup>4</sup>, creating difficulties in  
90 identifying pediatric cases and in contact tracing. These observations are in contrast with  
91 other respiratory virus infections (respiratory syncytial virus (RSV), influenza virus) where  
92 children are affected more commonly and more severely compared to adults<sup>5</sup>. Recently,  
93 a small family case study by Tosif *et al.*, indicated that children can mount an immune  
94 response with detectable antibodies to SARS-CoV-2 without preceding detectable viral  
95 load, therefore avoiding the development of a symptomatic SARS-CoV-2 infection<sup>6</sup>. The  
96 clinical differences observed in children and adults upon SARS-CoV-2 infection may be  
97 explained by several immune factors (amongst other clinical or physiological factors),  
98 such as pre-existing and cross-reactive immunity to common cold coronaviruses (CCC)<sup>7</sup>

99 with more recent exposure likely in children, immuno-senescence and inflammatory  
100 state<sup>8</sup>, innate immune responses, presence of auto-antibodies<sup>9</sup>, and “trained immunity”  
101 as a result of off-target effects of live attenuated vaccines for other infections<sup>5,10</sup>.  
102 Although a growing number of SARS-CoV-2 serology tests are currently in use worldwide  
103 and are the basis of the SARS-CoV-2 infection rate data, there is an absence of  
104 information on serological responses in children with RT-PCR confirmed SARS-CoV-2  
105 infection. Large epidemiological studies report that children only represent 1-2% of all  
106 SARS-CoV-2 cases<sup>11,12</sup> but this may be and underestimate because of differences in the  
107 development of the antibody responses to SARS-CoV-2 in children and pandemic  
108 response measures such as school closures. Serology is crucial for determining infection  
109 attack rates in the population and for assessing the response to a future vaccine to curb  
110 the global pandemic. Most serological tests available rely either on neutralizing antibodies  
111 or on the detection of antibodies targeting the Spike (S) or the Nucleocapsid (N) proteins  
112 of the virus<sup>13</sup>. We have previously demonstrated that antibodies that are directed against  
113 non-structural proteins of the virus, namely ORF3b and ORF8, can be used for accurate  
114 diagnosis of SARS-CoV-2 infection<sup>14</sup>. Whilst the cellular immune profile of children  
115 appears comparable to adults in a small case study<sup>6</sup>, there are no reports on the humoral  
116 antibody landscape and kinetics in pediatric cases. There is a lack of information on the  
117 SARS-CoV-2 antibody responses in adults or children to the virus accessory proteins, for  
118 instance ORF3b, ORF6 and ORF7a, which have been reported to be potent interferon  
119 antagonists that may play a role in immune evasion<sup>15-17</sup>. A finely tuned and balanced  
120 antibody response may impact COVID-19 outcomes, and the breadth and magnitude of

121 the landscapes of antibody responses to non-structural proteins may indicate the extent  
122 of virus replication and thus immune control.

123 In the present study, children and adults with SARS-CoV-2 RT-PCR confirmed infection  
124 were used to study the antibody landscape to a comprehensive panel of 14 different  
125 structural and accessory proteins by LIPS. We tested a population of 122 infected children  
126 and 36 infected adults in Hong Kong, including 58 patients with longitudinal samples (2  
127 to 4 time points, with a range 0 to 206 days post infection) to determine the longevity of  
128 the antibody responses. Furthermore, due to intensive contact tracing and case-finding  
129 measures in Hong Kong, asymptomatic cases with RT-PCR confirmed infections have  
130 been identified and their antibody responses are also profiled. These samples were  
131 collected between April to November 2020 and include predominantly the third wave of  
132 infection cases in Hong Kong corresponding to the period of July to September 2020. Our  
133 data reports to date, the most extensive data on the landscape and kinetics of antibody  
134 responses in COVID-19 children.

135 **Results**

136 **SARS-CoV-2 infected children have lower levels of antibodies than adults to all**  
137 **structural proteins, except E.**

138 We used the unbiased and quantitative LIPS platform to determine the antibody titres to  
139 an extensive panel of 14 antigens from structural and non-structural SARS-CoV-2  
140 proteins in plasma samples from a cohort of infected children, in comparison to adults  
141 and controls in Hong Kong (Table 1).

142 Our first data set represents COVID-19 cases of mixed timepoints and symptoms to  
143 determine the overall antibody landscapes in children (mean $\pm$ stdev: 39 $\pm$ 47 days, range:  
144 0-206 days), adults (mean $\pm$ stdev: 54 $\pm$ 20 days, range: 24-123 days) and negative  
145 controls. S and N antibodies are the most widely used antibodies in COVID-19 serology  
146 testing worldwide. We therefore first determined the levels of antibodies to different S  
147 sub-units by using 3 different S constructs in the LIPS assay: S1 which contains the RBD  
148 domain, S2 and the S2' cleaved subunit (Figure 1). The levels of the two Spike antibodies,  
149 S1 and S2' were markedly lower in children compared to the adult cohort ( $p < 0.0001$ ,  
150  $p = 0.0015$  and  $p < 0.0001$  respectively, Figure 1ac), whereas no difference was observed  
151 for S2 antibodies (Figure 1b). Moreover, N antibodies were significantly elevated in the  
152 pediatric COVID-19 cohort relative to negative controls (2.45e5 $\pm$ 2.8e5 LU versus  
153 4.15e4 $\pm$ 1.5e4 LU ( $p = 0.0045$ ), but did not reach the levels observed in the COVID-19 adult  
154 cohort that were almost half a log above (5.45e5 $\pm$ 3.0e5 LU adult COVID-19 cohorts,  
155  $p < 0.0001$ , Figure 1d).

156 We also assessed by LIPS antibodies to other structural proteins Matrix (M) and Envelope  
157 (E), which are not widely measured in serology. As for S1, S2', and N, we found that M



158 antibody levels were lower in the COVID-19 children compared to the adult COVID cohort  
159 ( $p < 0.0001$ , Figure 1e) but were significantly higher than seen in controls. E antibodies  
160 followed an inverted trend as they were significantly elevated in the pediatric COVID-19  
161 cohort (Figure 1f) compared to both adult COVID-19 ( $p = 0.0006$ ) and negative controls  
162 ( $p < 0.0001$ ).

163

164 **Increased breadth of accessory antigen targets in the pediatric COVID-19**  
165 **population.**

166 We next investigated the levels of antibodies directed against the non-structural protein  
167 1 (NSP1) and all the ORFs proteins of the virus. In line with our previous study<sup>14</sup>, adults  
168 with COVID-19 displayed elevated levels of NSP1, ORF3a, ORF3b, ORF7a, ORF7b, and  
169 ORF8 antibodies compared to negative controls ( $p < 0.0001$ ,  $p < 0.0001$ ,  $p < 0.0001$ ,  $p = 0.05$ ,  
170  $p = 0.0009$ ,  $p < 0.0001$ , Figure 2a-c and e-g). Again, no detectable levels of ORF6 and  
171 ORF10 antibodies were detected in the adult COVID-19 population ( $p = 0.8691$  and  
172  $p = 0.999$  respectively, Figure 2d and 2h). We observed that the COVID-19 children cohort  
173 displayed significantly lower levels of ORF3a, ORF7a, ORF7b antibodies than the adult  
174 COVID-19 cohort ( $p = 0.0001$ ,  $p < 0.0001$  and  $p < 0.0001$  respectively, Figure 2b, e-f). The  
175 magnitude of antibody responses to NSP1, ORF3b and ORF8 were comparable in the  
176 pediatric COVID-19 and adult COVID-19 populations, and significantly elevated  
177 compared to negative controls (Figure 2c and g).

178 Cumulative SARS-CoV-2 antibody responses from COVID-19 children and adults  
179 populations were then compared as percentages of the total SARS-CoV-2 structural and  
180 accessory antibody response. The anti-N antibodies substantially dominate the SARS-

181 CoV-2 humoral response detected by LIPS in both populations (Figure 2i-j), which is  
182 consistent with our previous findings in the adult population<sup>14</sup>. Due to the  
183 immunodominant effect of anti-N antibodies, we also performed analysis with or without  
184 N, both of which were highly significant ( $p < 0.0001$  Supplemental Figure 1b-e).  
185 Furthermore, representation of cumulative percentages of single specific antibodies to  
186 the global SARS-CoV-2 antibody response shows that the amount of the response  
187 towards the accessory proteins (NSP1 and ORFs) is increased over the response  
188 towards the structural ones in the pediatric COVID-19 population versus the adult COVID-  
189 19 population (8.81% versus 4.36% for the response to accessory proteins,  $p = 0.019$ ,  
190 Figure 2j) despite no significant differences in total IgG levels in both populations  
191 (Supplemental Figure 1a).

192

193 **Deciphering the SARS-CoV-2 antibody landscape differences in children and**  
194 **adults using clusters of points and principal component analysis.**

195 A cluster of points depicts each individual sample in a more complete way than a single  
196 statistical comparison, as it considers a combination of three (or more) different  
197 parameters taken together and the relevant relations of these parameters. To decipher  
198 the SARS-CoV-2 antibody landscape in children, we used relevant antibody  
199 combinations to represent the COVID-19 pediatric samples in clusters of points along  
200 with the negative and COVID-19 adult populations (Figure 3a-c and Supplemental figure  
201 2).

202 First, the cluster representing the three antibodies to the S subunit antigens S1, S2', S2  
203 confirmed that the pediatric population has a S antibody profile that is more closely  
204 comparable to negative controls (Figure 3a) than an adult COVID-19 response by LIPS  
205 (Figure 3b). Further cluster analysis of antibodies to S1, S2' with N, or other structural  
206 proteins N, M, and E reveals that the COVID-19 children population appears to be quite  
207 heterogeneous (Supplemental Figure 2a-b). Despite having a different profile than both  
208 the adult COVID-19 and the negative populations, the pediatric population cannot be  
209 clearly discriminated.

210 We then selected accessory protein antibodies as combinations to investigate the  
211 relevance of under-utilized markers. ORF3b and ORF8 antibodies were selected, along  
212 with N antibodies, as both were previously shown to discriminate accurately COVID-19  
213 adults from negative controls<sup>14</sup>. The (N, ORF3b, ORF8) cluster of points can accurately  
214 allow the positive discrimination of the pediatric COVID-19 cases from the negatives  
215 (Figure 3c). Indeed, in the (N, ORF8; x, y) plane, the negative population is separated  
216 from the adult and pediatric positive ones by two-segments of straight lines (equations of  
217  $830 \cdot \log(N) + 0.3843 \cdot \text{ORF8} = 4801$  and  $-350 \cdot \log(N) + 1.036 \cdot \text{ORF8} = 790$ , with all positive  
218 samples represented above or on these lines, and only one negative sample being above  
219 these lines). Then, using the (ORF3b, ORF8; y, z) plane, again, two-segments of straight  
220 lines (equations of  $0.035 \cdot \text{ORF3b} + 0.1334 \cdot \text{ORF8} = 409.284$  and  
221  $0.074 \cdot \text{ORF3b} + 0.0437 \cdot \text{ORF8} = 221.812$ ) separate the negative samples from the adult  
222 and pediatric positive ones. Therefore, the (N, ORF3b, ORF8) cluster reveals that the  
223 pediatric COVID population resembles a COVID-19 adult population and can be  
224 discriminated from negative pre-pandemic controls. Importantly, this is the only

225 combination that allowed us this discrimination, as other parameter combinations (e.g.  
226 (N, S1, S2'), (N, E, M) in Supplemental Figure 2) and combinations of antibodies to  
227 accessory proteins) were also tested and represented as clusters of points but did not  
228 discriminate pediatric samples. These data cluster analysis show that the antibody  
229 landscape of the COVID-19 children population is distinct from the adult one.

230 To test the hypothesis that the antibody landscape to structural and accessory viral  
231 proteins drives the distinct profile of the pediatric population, we undertook a principal-  
232 component analysis (PCA) of the 14 SARS-CoV-2 antibodies for the full data set (from  
233 Figure 1 and 2). Dimension (principal component) 1 and 2 explained respectively 21%  
234 and 15% of the total variances from all the 14 antibody types (Figure 3d-e). Accessory  
235 proteins ORF3b, NSP1, ORF8, ORF3a, ORF7a, ORF6 and ORF10 had high correlation  
236 values (Supplemental table 1), reflecting that antibodies to structural proteins do not  
237 solely drive the principal component 1. Particularly, contributions of ORF3b, NSP1, ORF8,  
238 ORF3a were the highest in Dimension 1 (Dim1, Figure 3de). Moreover, PCA showed that  
239 ORF3b and ORF7a antibodies highly contributed to the differences seen in both  
240 dimensions (Figure 3d) highlighting their importance in the serological response.

241 Strikingly, the PCA revealed that pediatric COVID-19 antibody response was also  
242 intermediate between COVID-19 adults and negatives (Figure 3f). Indeed, the normal-  
243 probability representation of the 3 populations showed that only 18.9% of the pediatric  
244 patients overlapped with the ellipse of the COVID-19 adults and only 3.54% overlapped  
245 with the ellipse of the negatives (Figure 3f). Further analysis on gender, time-point,  
246 symptoms and neutralization data (PRNT90) values reported that these were not

247 significant factors in discriminating the data (Supplemental Figure 3). Therefore, the  
248 differences in the observed SARS-CoV-2 antibody responses is primarily explained by  
249 the age and type of patients: pediatric COVID-19, adult COVID-19 or pre-pandemic  
250 negative controls.

251  
252 **No difference in antibody responses between symptomatic and asymptomatic**  
253 **COVID-19**

254 To assess the potential effect of antibodies to structural and non-structural proteins of  
255 SARS-CoV-2, we further stratified data (from Figure 1 and 2) into symptomatic  
256 (mild/severe) and asymptomatic for both the adult and pediatric cohorts.  
257 We found no differences in antibody responses between asymptomatic and mild COVID-  
258 19 children for all 14 antigens. In adults, we observed the same trend excluding ORF3a  
259 antibody levels which are higher for symptomatic patients ( $p=0.0403$ , Figure 4b). More  
260 importantly N, M, ORF3a and ORF7b antibody levels in asymptomatic children versus  
261 asymptomatic adults were not significantly different ( $p=0.5673$ ,  $p=0.2669$ ,  $p=0.9185$  and  
262  $p=0.0859$  respectively, Figure 4), whilst symptomatic adults had an upregulated antibody  
263 response to these antigens compared to symptomatic children ( $p<0.0001$  for all 4  
264 antigens, Figure 4 and Supplemental Figure 4a).

265  
266 **Antibody landscapes at early infection and long-term stability**

267 We previously observed that the SARS-CoV-2 antibody responses can vary in magnitude  
268 and specificity in adults between acute and convalescent to memory time-points<sup>14</sup>. To

269 study the effect of time in the pediatric COVID-19 population, we stratified pediatric  
270 responses of all 254 samples (Figures 1 and 2) by early (<d14) versus later ( $\geq$ d14) time-  
271 points (Figure 5). S2, N and ORF7a specific antibodies were significantly increased after  
272 day 14 post symptom onset. In contrast, ORF3b and ORF7b antibodies elicited a higher  
273 antibody response prior to day 14 (Figure 5b). Finally, responses to structural proteins  
274 S1, S2, M and E and accessory proteins NSP1, ORF3a, ORF6 and ORF8 were  
275 comparable before and after day 14 (Figure 5ab).

276 To further confirm the stability of SARS-CoV-2 specific antibodies we used 146  
277 longitudinal paired samples of 58 pediatric patients that had either 2, 3 or 4 blood draws  
278 (Figure 6a). The time-frame of sampling ranged from 0 to 206 days post-symptom onset,  
279 with the majority of samples from <14 days (n=63), or long term memory samples after  
280 day 60 (n=58) (Figure 6b). Using a linear mixed effects model, we determined that  
281 antibody responses to structural proteins S1, S2, S2', M and E were stable over time,  
282 whereas N was significantly increased ( $p<0.001$ ) (Figure 6c). Furthermore, antibodies  
283 towards non-structural proteins NSP1, ORF3a, ORF3b and ORF7a also significantly  
284 increased over time ( $p<0.001$ ,  $p=0.001$ ,  $p=0.027$  and  $p=0.002$  respectively), whilst ORF6,  
285 ORF8 and ORF10 were stable (Figure 6c). Only ORF7b antibody response significantly  
286 decayed longitudinally at a slow rate ( $p<0.001$ , Figure 6c). In order to determine whether  
287 the slope of each serological marker could inform the disease outcome we compared  
288 asymptomatic and symptomatic patients but no significant differences were found ( $p>0.05$   
289 for all) (Supplemental figure 4).

290

291

292

293 **A distinct antibody landscape may impact IFN $\alpha$  levels**

294 Severe COVID-19 disease is associated with low IFN $\alpha$  responses in adults which has  
295 been linked to the type-I IFN down-regulation roles of ORF3b, ORF7a and ORF6<sup>15-17</sup>.  
296 Antibodies to these 3 proteins in a cluster of points (ORF3b, ORF7a, ORF6 as  $x,y,z$ ),  
297 show that children have a heterogenous humoral profile towards these 3 type-I IFN down-  
298 regulators (Figure 7a). To assess the IFN $\alpha$  response a quantitative ELISA was conducted  
299 on plasmas collected before day 7 in children (n=48) and adults (n=18) (Figure 7b). We  
300 observed a significant decrease of acute IFN $\alpha$  levels in children compared to the adult  
301 samples (p=0.0165, Figure 7b), with only 3 pediatric samples showing a detectable IFN $\alpha$   
302 level. To further investigate the antibody profiles with IFN $\alpha$  responses, the total antibody  
303 response of these 3 IFN $\alpha$  producing children compared to the non-responder children  
304 (n=45), we plotted the average antibody responses to all 14 antigens for each group  
305 (Pediatric IFN $\alpha^-$  versus Pediatric IFN $\alpha^+$ , average: Figure 7c, and individuals:  
306 Supplemental figure 6). We found a significant difference in the antibody distribution in  
307 the 3 IFN $\alpha$  producing children versus the IFN $\alpha$  non-producing children (IFN $\alpha^+$  versus  
308 IFN $\alpha^-$ , p<0.0001), with IFN $\alpha^+$  children having increased ORF6, ORF7a and ORF3b  
309 antibodies, and lower ORF8 and E antibody levels. Notably ORF6 antibody levels were  
310 particularly higher in one IFN $\alpha^+$  asymptomatic child with low viral loads (Figure 7d).

311

## 312 **Discussion**

313 Young children account for only a small percentage of reported and medically attended  
314 COVID-19 infections<sup>5</sup>, which is unlikely to be completely explained by reduced exposures  
315 and school closures. This difference is likely contributed to by differences in host  
316 responses between children and adults. We present herein the most comprehensive  
317 study to date of the magnitude, specificity and duration of SARS-CoV-2 specific  
318 antibodies in children.

319 While the understanding of immunity to COVID-19 is growing at a fast pace,  
320 information on the pediatric population remains limited largely due to their asymptomatic  
321 and mild illness compared to the adult population. Furthering our understanding of the  
322 immune mechanisms that lead to this mild clinical presentation could represent new  
323 alternative therapeutics, prevention methods or improved diagnostics. Our work enables  
324 unique serological insights on the long-term response and asymptomatic infections as  
325 Hong Kong's pandemic control strategy has intensive testing, contact tracing and isolation  
326 of all COVID-19 cases including asymptomatic and mild cases with longitudinal follow up.  
327 This has provided us the opportunity to investigate a cohort of children with both  
328 symptomatic and asymptomatic children. We describe the antibody diversity between day  
329 0 and day 206 post-symptom onset, and reveal major differences in the antigens targeted  
330 by the humoral immune response of COVID-19 children compared to adults which may  
331 indicate differences in viral protein propagation kinetics, pathogenesis and IFN immune  
332 evasion.

333 Importantly, we report that the proportion of the antibody response targeting the  
334 accessory proteins is significantly increased in children versus adults. Antibodies to the



335 N structural protein largely dominate the humoral immune response both in children and  
336 adults, though the total magnitude of the N-specific antibodies in children is substantially  
337 lower than adults. Visualization of N antibody levels in our cluster representations clearly  
338 show that only half of the pediatric cases have comparable levels of these antibodies to  
339 adults. Others have also reported a reduced magnitude of N antibodies in children and  
340 they suggested that this observation could be related to a lower release of N proteins  
341 related to lower replication in children<sup>18</sup>. On the contrary, our data show that children  
342 produce antibodies to some accessory proteins (namely NSP1, ORF3b and ORF8) at  
343 similar levels to adults, and to structural protein E in higher proportions than adults, the  
344 latter notorious for high turnover due to its pivotal role in viral propagation (reviewed in<sup>19</sup>).  
345 Therefore, these accessory proteins are not being released to a lesser extent in children  
346 but may reflect different virus pathogenesis in children compared to adults. Viral loads  
347 have been shown to be comparable in children and adults, which may reflect similar levels  
348 of viral replication<sup>2</sup>.

349 For the Spike subunits antibodies, the (S1, S2', S2) cluster reveals that the children  
350 population resembles a negative pre-pandemic population and not a COVID-19 adult one.  
351 A recent study describes a lower anti-S IgG, IgM, IgA in the pediatric population which  
352 correlates with our findings<sup>20</sup>. One explanation on the clinical difference between children  
353 and adults raise that the pre-existing immunity against seasonal human coronaviruses  
354 (HCoVs) that cross-reacts with SARS-CoV-2 is higher in children, as they have a higher  
355 infection rate of seasonal HCoVs than adults<sup>21</sup>. Individuals exposed and unexposed to  
356 SARS-CoV-2 have cross-reactive antibodies against the proteins of SARS-CoV-2 and  
357 seasonal HCoVs<sup>22,23</sup>. Moreover because circulating HCoVs have a higher homology to

358 SARS-CoV-2 structural proteins than non-structural proteins (if they exist)<sup>24,25</sup>, we would  
359 expect a higher cross-reactivity for structural proteins based on pre-existing immunity.  
360 SARS-CoV-2 infection back-boosts antibodies against conserved epitopes, including the  
361 relatively conserved fusion peptide of the Spike S2 subunit<sup>22,23</sup>. In our hands, COVID-19  
362 children and adults had comparable levels of S2 antibodies, contrary to S1 and S2', which  
363 shows a possible effect of pre-existing HCoV's immunity for more conserved domains of  
364 S such as S2.

365 Our observations of lower Nucleocapsid and Spike antibodies in COVID-19 children may  
366 indicate that there may be lower sensitivity of serological detection for SARS-CoV-2 when  
367 using assays based on S and/or N alone, leading to an underestimation of SARS-CoV-2  
368 exposed children. S antibodies have been reported in lower magnitude in the majority of  
369 mild adult infections, with higher levels being produced in severe cases<sup>26</sup>, which is  
370 consistent with our data on low S antibody levels in children which were also  
371 asymptomatic or mild clinical scores. Low antibody levels and low affinity have been  
372 associated with Antibody Dependent Enhancement by facilitation of viral uptake by host  
373 cells<sup>27</sup>, however yet no definitive evidence of ADE for SARS-CoV-2 neither in adults nor  
374 in children has been brought forward<sup>28</sup>, but warrants further investigation.

375 The plane (ORF3b/ORF8) in the cluster of points (N, ORF3b, ORF8) reveals that children  
376 samples have specific combinatory values of these two antibodies that is consistent with  
377 adult populations, and that makes them distinguishable from the negatives. Similar to  
378 NSP1, we report the proportion of all non-structural antibodies makes a greater  
379 contribution of the SARS-CoV-2 response in children than in adults. The Principal  
380 Component Analysis of our dataset confirmed further the importance of antibodies to

381 accessory proteins in characterising the pediatric samples. Whether these antibodies to  
382 accessory proteins play a role in the virus infectivity or in the pathogenesis of the disease  
383 and in the milder outcome of SARS-CoV-2 infection in children presents further questions  
384 for investigations.

385 ORF3b, ORF7a and ORF6 proteins have been previously reported to play a role in cellular  
386 type-1 IFN down-regulation<sup>15-17</sup>. The cluster representation of ORF3b, ORF7a and ORF6  
387 antibodies shows a different pattern between adult and children population. Furthermore,  
388 the PCA revealed that ORF7a and ORF3b contributed highly to component 1 and 2 (Dim1  
389 and Dim2) which accounted for 21% and 15% of the variances observed respectively,  
390 pointing to a potential pivotal role of these antigens. In all COVID-19 infected children or  
391 adults tested at early timepoints of infection (< day 7), the majority did not elicit a  
392 detectable IFN $\alpha$  response, in line with previous findings<sup>30</sup>, but overall children IFN $\alpha$   
393 responses were significantly lower than the adult ones. Amongst the IFN $\alpha$  responders  
394 and non-responders in children a different antibody landscape suggests possible  
395 functions of these markers in counteracting viral IFN down-regulation, with ORF6  
396 antibody responses doubled in IFN $\alpha$ <sup>+</sup> children. Bastard *et al.*, reported anti-type I  
397 interferon auto-antibodies in a subset of severe COVID-19 patients<sup>9</sup>. Moreover, a recent  
398 study has linked high levels of auto-immunity with COVID-19 severe cases in adults<sup>31</sup>. As  
399 children are less predisposed to auto-immunity than adults<sup>32</sup>, it is possible this contributes  
400 to their milder clinical presentation along with the diversified antibody landscape observed  
401 in our study.

402 We report in children diverse antibody profiles in early versus late samples and the  
403 maintenance or increase of all antibodies to structural and accessory proteins, except

404 ORF7b antibodies, for at least 6 months post-infection. Many factors play a role in  
405 antibody long-term persistence, such as antigen release, antigen presentation, induction  
406 of a germinal centre reaction and a memory B cell pool<sup>33</sup>. Additional studies on viral  
407 proteins release, their roles and their specific B cells are needed to fully understand the  
408 antibody landscape in children.

409 Our cohort did not include any case of Multi-inflammatory System in Children (MIS-C).  
410 Although one study reported that no distinct antibody response was observed between  
411 MIS-C and mild or asymptomatic children<sup>18</sup>, it only measured S and N antibodies.  
412 Therefore it would be of interest to study the whole spectrum of antibodies in this  
413 population and particularly those targeting accessory proteins. In our hands, symptomatic  
414 children have significant differences in antibody levels versus symptomatic adults only for  
415 selected antibodies (N, M, ORF3a and ORF7b) which suggests that these markers could  
416 play a role in infection control or infectivity.

417 It is possible that the interest for antibodies to SARS-CoV-2 internal proteins will grow  
418 with the rollout of sub-unit Spike only vaccines, in order to allow the distinction between  
419 SARS-CoV-2 past exposure and vaccination in specific populations and to create an  
420 estimated date of exposure given the unique rate of waning of different specificities. The  
421 emergence of certain viral mutants such as the ORF8 truncations<sup>34</sup> or recent ORF3b  
422 deletions<sup>35</sup> could modify the contributions of certain ORFs, their antibodies responses  
423 could also be used for epidemiology studies on the insurgence of different strains of the  
424 virus.

425 In conclusion, we report the description of a more diversified antibody landscape  
426 in the COVID-19 children population compared to adults, with an increased and sustained

427 humoral response to all accessory proteins of the virus. This study of antibody spectrum  
428 provides insights into the importance of the breadth of responses and how it differs  
429 between children and adult that have diverse outcomes of infection, and could inform  
430 improved SARS-CoV-2 diagnostics for the pediatric population.

## 431 **Methods**

### 432 **Patients and samples collection**

433 Our study enrolled a total of 122 children patients and 36 adult patients based on  
434 recruitment of available patients with RT-PCR confirmed COVID-19 infection in Hong  
435 Kong. We used a total of 254 COVID-19 children plasma samples including 146  
436 longitudinal samples from 58 subjects with 2 to 4 sampling time points, and 119 early  
437 time-points samples (< day 14). Samples were used from children (mean±stdev: 39±47  
438 days, range: 0-206 days) and adults (mean±stdev: 54±20 days, range: 24-123 days), with  
439 the sample day was defined as day post-symptom onset or RT-PCR confirmation for  
440 asymptomatic cases through contact tracing or quarantine. For measurement of IFN $\alpha$ , an  
441 extra set of 18 COVID-19 adult patients sampled prior to day 7 was used in comparison  
442 to 48 samples that were collected prior to day 7 in the COVID-19 pediatric cohort. The  
443 COVID-19 patient study was approved by the institutional review board of the respective  
444 hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central /  
445 Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW  
446 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster  
447 Clinical Research Ethics Committee (CREC 2020.229). All of patients provided informed  
448 consent.

449 The negative control plasma samples used in this study were from Hong Kong  
450 blood donors collected from June to August 2017 (prior to the emergence of COVID-19),  
451 used a total of 33 plasma samples including negative pediatric samples (n=20) and  
452 negative adult samples (n=13). The collection of negative control blood donors was  
453 approved by the Institutional Review Board of The Hong Kong University and the Hong

454 Kong Island West Cluster of Hospitals (approval number: UW16-254). Plasma samples  
455 were collected from heparinized blood. All samples from COVID-19 patients or negative  
456 controls were heat-inactivated prior to experimental use at 56°C for 30 minutes. Details  
457 on the sample cohort are presented in Table 1.

458

### 459 **SARS-CoV-2 cloning and (Ruc)-antigen expression**

460 Based on previous studies describing the structure of the SARS-CoV-2 genome<sup>25,36</sup>, an  
461 extensive panel of 14 proteins (S1, S2, S2', E, M, N, NSP1, ORF3a, 3b, 6, 7a, 7b, 8, 10)  
462 was chosen for antibody testing by LIPS. Primers and cloning for the amplification of  
463 SARS-CoV-2 proteins were as previously described<sup>14</sup>. Constructs with pREN2-Renilla  
464 luciferase plasmid containing the SARS-CoV-2 antigen of interest were transfected into  
465 Cos1 cells and prepared as previously described<sup>14</sup>.

466

### 467 **Measurement of antibody responses using LIPS**

468 The LIPS assays were performed following the protocol of Burbelo *et al.*, with the following  
469 modifications<sup>36</sup>, as previously described<sup>14</sup>. Briefly, (Ruc)-antigen (at an equal  
470 concentration for each antigen at  $10^7$  per well) and plasma (heat inactivated and diluted  
471 1:100) were incubated for 2 hours with shaking at 800rpm. Ultralink protein A/G beads  
472 (Thermo-Fisher) were added to the (Ruc)-antigen and serum mixture in a 96-deep-well  
473 polypropylene microtiter plate and incubated for 2 hours with shaking at 800rpm. The  
474 entire volume was then transferred into HTS plates (Millipore) and washed as previously  
475 described. The plate was read using QUANTI-Luc Gold substrate (Invivogen) as per  
476 manufacturer's instructions on a Wallac MicroBeta JET luminometer 1450 LSC &

477 Luminescence counter and its software for analysis (PerkinElmer). Experimental controls  
478 include no plasma blank wells with (Ruc)-antigens and negative control serum from  
479 healthy donors plasma collected prior to the COVID-19 pandemic. The background  
480 corresponds to the LU signal from each Ruc-fusion antigen with protein A/G and substrate  
481 with no plasma.

482

### 483 **Enzyme-linked immunosorbent assay**

484 Total IgG were measured in plasma samples using the Total human IgG ELISA kit  
485 (Thermo-Fisher) at a final dilution of 1:500,000 according to manufacturer's instructions.  
486 IFN- $\alpha$  was measured in plasma samples using the Human IFN- $\alpha$  Platinum ELISA kit  
487 (Invitrogen) at a dilution of 1:5 according to manufacturer's instructions.

488

### 489 **Clusters of points**

490 The SARS-CoV-2 antibodies dataset has been treated through the free software  
491 ConTeXt, with LuaMetaTeXengine (version 2020.05.18) developed by Hans Hagen  
492 (<http://www.pragma-ade.nl>) which uses TeX, Metapost and Lua to obtain the 3D clusters  
493 of points shown in Figure 3abc, Figure 7c and Supplemental Figure 2. For clarity, only the  
494 first 144 COVID-19 pediatric samples of the dataset are represented in the clusters of  
495 points, along with n=36 COVID-19 adult samples and n=28 negatives.

496 In the cluster (N, ORF3b, ORF8), the equations of the red lines are: (1) in the plane (N,  
497 ORF8) :  $830 \cdot \log(N) + 0.3843 \cdot \text{ORF8} = 4801$  and  $-350 \cdot \log(N) + 1.036 \cdot \text{ORF8} = 790$ , and (2)  
498 in the plane (ORF3b, ORF8):  $0.035 \cdot \text{ORF3b} + 0.1334 \cdot \text{ORF8} = 409.284$  and



499  $0.074*ORF3b+0.0437*ORF8=221.812$ . These straight lines allow the most accurate  
500 discrimination between negative controls and positive adult populations.

501

## 502 **Principal component analysis**

503 The LU for 14 antigens were log-scale transformed (the negative and zero values in the  
504 data set were replaced by 1) prior to PCA analysis. The missing values in the dataset  
505 were estimated by a probabilistic model<sup>37</sup>. The probabilistic model is tolerant to amounts  
506 of missing values between 10% to 15% which is fit for our data. The missing data was  
507 estimated using *pcaMethods* (version 1.80.0)<sup>38</sup>. The completed data were standardized  
508 (scaled) before input in standard PCA (using *FactoMineR* (version 2.4)<sup>39</sup>.. The PCA  
509 results were extracted and visualized using *factoextra* (version 1.0.7)<sup>40</sup>.

510

## 511 **Statistics and Reproducibility**

512 GraphPad Prism version 8 software (San Diego, CA) was used for statistical analysis. All  
513 experiments were repeated twice independently. Antibody levels are presented as the  
514 individual responses and geometric mean +/- standard deviation (stdev). Ordinary one-  
515 way ANOVA with Tukey's multiple comparison test were performed to compare the  
516 pediatric, adult and negative populations in Figures 1 and 2, and the early and late  
517 samples in Figure 5. For Figure 2j, percentages were calculated by dividing each mean  
518 antibody value by the sum of the total antibody responses, and compared using a Chi-  
519 square test between the "observed" (pediatric) versus "expected" (adult) distributions.  
520 For Figure 6c and Supplementary figure 3, a linear mixed effects model was fitted to  
521 account for correlated responses for the longitudinal samples dataset.  $\text{Log}_{10}$  LIPS was

522 used for the analysis (as dependent variable) to reduce the impact of extreme values/non-  
523 normality. For Supplementary figure 1, the distributions showed in the pie-charts were  
524 compared using a Chi-square test between the “observed” (pediatric) versus “expected”  
525 (adult) distributions.

526

### 527 **Data availability statement**

528 The data that support the findings of this study are available from the corresponding  
529 author upon request.

530

531 **Figure legends**

532 **Figure 1. Comparison of antibody responses to SARS-CoV-2 structural proteins in**  
533 **children and in adults with COVID-19.** Antibodies against the SARS-CoV-2 structural  
534 proteins Spike S1 subunit (S1) (a), Spike S2 subunit (b), Spike S2' subunit (c),  
535 Nucleocapsid (N) (d), Membrane (M) (e), and Envelope (E) (f) were measured by LIPS  
536 from samples from pediatrics COVID-19 (n=254) or adult patients (n=36), and negative  
537 controls (n=33). Background no plasma values were subtracted. Experiments were  
538 repeated twice. All data represents individual responses, and the mean +/- stdev. Two-  
539 sided P values were calculated using the Mann-Whitney U test. \* shows statistical  
540 significance between COVID-19 patients versus negative controls. \*\*p<0.01, \*\*\*p<0,001,  
541 \*\*\*\* p<0,0001.

542

543 **Figure 2. Antibody responses to SARS-CoV-2 non-structural proteins and ORFs are**  
544 **lower in magnitude in children than in adults with COVID-19 but represent globally**  
545 **a higher proportion of the SARS-CoV-2 humoral response.** Antibodies against NSP1  
546 (a) (in ORF1ab), and other ORFs (ORF3a (b), ORF3b (c), ORF6 (d), ORF7a (e), ORF7b  
547 (f), ORF8 (g) and ORF10 (h)) were measured in pediatric (n=254) and adult (n=36)  
548 COVID-19 cases and negative controls (n=33) by LIPS to cover all the ORFs of the virus.  
549 (i) A heatmap comparing the mean titres (LU) for structural (N, S, S1, S2', S2, M, E) and  
550 accessory proteins (NSP1, ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF10) responses  
551 in the COVID-19 pediatric and adult populations and Negatives. (j) Percentages of single  
552 antibody levels to SARS-CoV-2 antigens of the cumulative SARS-COV-2 antibody  
553 response in COVID-19 children and adults for the 14 antigens. Experiments were

554 repeated twice. Two-sided P values were calculated using the Mann-Whitney U test. \*  
555 shows statistical significance between COVID-19 patients versus negative controls.  
556 \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ , \*\*\*\*  $p < 0,0001$ . Data in (a-h) represents the individual  
557 responses and mean +/- stdev, data in (i) represents mean values (LU), data in (j)  
558 represents percentages.

559

560 **Figure 3. Representation of the pediatric COVID-19 population as a cluster of points**

561 **for relevant antibody combinations and Principal Component Analysis (PCA).** (a-

562 b). Cluster representation of S1, S2', S2 antibodies combination. (a) shows the pediatric

563 COVID-19 population versus the adult COVID-19 population, (b) shows the pediatric

564 COVID-19 population versus the negative population. (c) Cluster representation of N,

565 ORF3b, ORF8 antibodies combination, for the pediatric COVID-19 population versus the

566 adult COVID-19 population and the negative population. Patients are presented

567 according to their values of SARS-CoV-2 individual LIPS antibodies as  $(x, y, z)$  in the

568 space. Pediatric COVID-19 patients ( $n=144$ ) are represented as red dots. COVID-19 adult

569 patients ( $n=36$  in (a-b) and  $n=24$  in (c)) are represented in blue. The negative population

570 ( $n=28$ ) is represented in gray. (d-f) PCA of 14 antibodies analyzed in COVID-19 pediatric

571 patients. Dim1 explains 21% of the variation, while Dim2 explains 15% of the variation.

572 (d) Correlation circle and contributions. The scale of contributions is indicated (right). (e)

573 Contribution of variables on dimensions 1 and 2. The red dashed line on the graph above

574 indicates the expected average contribution. (f) Factorial plot of PCA on dimension 1 and

575 2. The plot is colored by sample types, the largest point in shape in each group is the

576 group mean point (circle is for Adult positives, triangle for Negatives and squares for  
577 Pediatric positives).

578

579 **Figure 4. Asymptomatic and mildly symptomatic children do not display different**

580 **antibody landscapes.** Pediatric and adult samples were stratified according to the

581 symptom score of the patients (asymptomatic « asymppto » (pediatric COVID-19 n=98,

582 adults COVID-19 n=9) versus symptomatic « sympto » (pediatric COVID-19 n=156,

583 adults COVID n=27)), data from Figure 1 and 2 were analyzed according to “asymppto”

584 and “sympto”. (a) Antibodies against the SARS-CoV-2 structural proteins S1, S2, S2', N,

585 E, and M by LIPS. (b) Antibodies against SARS-COV-2 NSP1 (in ORF1ab), and all other

586 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). Two-sided P values

587 were calculated using the Mann-Whitney U test. \* shows statistical significance between

588 COVID-19 patients versus negative controls. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\*

589 p<0,0001. All data represent individual responses and the mean +/- stdev.

590

591 **Figure 5. A unique antibody landscape is specific of early time-point samples (<**

592 **day 14).** Pediatric samples were stratified according to the time-point of collection, and

593 data from Figure 1 and 2 were analyzed according to acute (<day 14, n=119) and later

594 time-points (≥day 14, n=135). (a) Antibodies against the SARS-CoV-2 structural proteins

595 S1, S2, S2', N, E, and M by LIPS. (b) Antibodies against NSP1 (in ORF1ab), and all other

596 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). P values were

597 calculated using the student t test. \* shows statistical significance between acute time-

598 point pediatric COVID-19 patients versus late time-point pediatric COVID-19 patients.

599 \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\* p<0,0001. All data represent individual responses and  
600 the mean +/- stdev.

601  
602 **Figure 6. Longitudinal stability of antibody responses for structural and non-**  
603 **structural SARS-CoV-2 proteins in COVID-19 children.** (a) Number of longitudinal  
604 patients with either 2, 3 or 4 blood draws from 58 pediatric COVID-19 cases. (b) Sample  
605 collection time-line (days post infection). (c) A linear trend on log<sub>10</sub> LIPS values was fitted  
606 for longitudinal samples for S1, S2', N, M E, NSP1, ORF3a, ORF3b, ORF7a, ORF7b,  
607 ORF8 (n=58 pediatric COVID-19 patients).

608  
609 **Figure 7. IFN- $\alpha$  producing pediatric patients display a different landscape of**  
610 **antibody response to SARS-CoV-2 accessory proteins.** (a) Cluster representation of  
611 antibodies to the accessory proteins ORF3b, ORF7a, ORF6 (x, y, z) for the COVID-19  
612 pediatric samples (red, n= 144) versus the COVID-19 adult samples (blue, n= 27). (b)  
613 Plasma IFN- $\alpha$  concentrations (pg/ml) in pediatric (n=48) and adult COVID-19 cases  
614 (n=18) early timepoint samples (< day 7). Data represents individual responses and the  
615 mean +/- stdev. (c) Pie charts of the cumulative antibody responses to the relevant SARS-  
616 CoV-2 structural and non-structural protein antigens (excluding N) in COVID-19 pediatric  
617 cohort stratified (positive/negative) by their IFN- $\alpha$  responses. (d) Individual data for IFN-  
618  $\alpha^+$  pediatric cases viral loads by RT-PCR, ORF3, ORF6, and ORF7b LIPS LU. P values  
619 were calculated using Chi-squared test between the mean of IFN $\alpha$ - pediatric COVID-19  
620 patients (N=45) and the IFN $\alpha^+$  (N=3). ns, p=0.0591 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*  
621 p<0.0001.

## 622 **Acknowledgements**

623 The authors thank the patients and their families for their participation, and are grateful to  
624 the hospital staff, clinicians and nurses, particularly Karen YS Yui, for sample  
625 coordination. We thank Professor JT Wu, Dr Mahen RP Perera and Dr Kathy Leung for  
626 providing donor plasma controls. This study was partly supported by the Theme based  
627 Research Grants Scheme (T11-712/19-N), Health and Medical Research Fund (HMRF  
628 COVID-190115 and COVID-190126), National Institutes of Allergy and Infectious  
629 Diseases, National Institutes of Health (USA) (contract HHSN272201400006C).

630

## 631 **Ethics declaration**

632 The COVID-19 patient study was approved by the institutional review board of the  
633 respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon  
634 Central / Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West  
635 Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories  
636 East Cluster Clinical Research Ethics Committee (CREC 2020.229). All of patients  
637 provided informed consent. The collection of plasma from blood donors serving as  
638 controls was approved by Institutional Review Board of The Hong Kong University and  
639 the Hong Kong Island West Cluster (UW16-254).

640

## 641 **Competing interests**

642 A Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed an IDF (US  
643 63/016,898) for the use of ORF8 and ORF3b as diagnostics of SARS-CoV-2 infection.

644

## 645 References

- 646 1. Vabret, N., *et al.* Immunology of COVID-19: Current State of the Science. *Immunity*  
647 **52**, 910-941 (2020).
- 648 2. Jones T.C. , M.B., Veith T. , Guido Biele, Marta Zuchowski, Jörg Hoffmann, Angela  
649 Stein, Anke Edelmann, Victor Max Corman, Christian Drosten. An analysis of  
650 SARS-CoV-2 viral load by patient age. *medRxiv* (2020).
- 651 3. Valverde, I., *et al.* Acute Cardiovascular Manifestations in 286 Children with  
652 Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in  
653 Europe. *Circulation* (2020).
- 654 4. Qiu, H., *et al.* Clinical and epidemiological features of 36 children with coronavirus  
655 disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.  
656 *Lancet Infect Dis* **20**, 689-696 (2020).
- 657 5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review  
658 of the proposed mechanisms underlying the age-related difference in severity of  
659 SARS-CoV-2 infections. *Arch Dis Child* (2020).
- 660 6. Tosif, S., *et al.* Immune responses to SARS-CoV-2 in three children of parents with  
661 symptomatic COVID-19. *Nat Commun* **11**, 5703 (2020).
- 662 7. Gorse, G.J., Donovan, M.M. & Patel, G.B. Antibodies to coronaviruses are higher  
663 in older compared with younger adults and binding antibodies are more sensitive  
664 than neutralizing antibodies in identifying coronavirus-associated illnesses. *J Med*  
665 *Virol* **92**, 512-517 (2020).
- 666 8. Freeman, T.L. & Swartz, T.H. Targeting the NLRP3 Inflammasome in Severe  
667 COVID-19. *Front Immunol* **11**, 1518 (2020).
- 668 9. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-  
669 threatening COVID-19. *Science* **370**(2020).
- 670 10. Netea, M.G., *et al.* Trained Immunity: a Tool for Reducing Susceptibility to and the  
671 Severity of SARS-CoV-2 Infection. *Cell* **181**, 969-977 (2020).
- 672 11. Parri, N., Lenge, M., Buonsenso, D. & Coronavirus Infection in Pediatric  
673 Emergency Departments Research, G. Children with Covid-19 in Pediatric  
674 Emergency Departments in Italy. *N Engl J Med* **383**, 187-190 (2020).
- 675 12. Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons From the  
676 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report  
677 of 72314 Cases From the Chinese Center for Disease Control and Prevention.  
678 *JAMA* **323**, 1239-1242 (2020).
- 679 13. Rikhtegaran Tehrani, Z., *et al.* Performance of nucleocapsid and spike-based  
680 SARS-CoV-2 serologic assays. *PLoS One* **15**, e0237828 (2020).
- 681 14. Hachim, A., *et al.* ORF8 and ORF3b antibodies are accurate serological markers  
682 of early and late SARS-CoV-2 infection. *Nat Immunol* **21**, 1293-1301 (2020).
- 683 15. Martin-Sancho, L., *et al.* Functional Landscape of SARS-CoV-2 Cellular  
684 Restriction. *bioRxiv* (2020).
- 685 16. Konno, Y., *et al.* SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose  
686 Activity Is Increased by a Naturally Occurring Elongation Variant. *Cell Rep* **32**,  
687 108185 (2020).
- 688 17. Yuen, C.K., *et al.* SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent  
689 interferon antagonists. *Emerg Microbes Infect* **9**, 1418-1428 (2020).



- 690 18. Weisberg, S.P., *et al.* Distinct antibody responses to SARS-CoV-2 in children and  
691 adults across the COVID-19 clinical spectrum. *Nat Immunol* (2020).
- 692 19. Schoeman, D. & Fielding, B.C. Is There a Link Between the Pathogenic Human  
693 Coronavirus Envelope Protein and Immunopathology? A Review of the Literature.  
694 *Front Microbiol* **11**, 2086 (2020).
- 695 20. Weisberg, S.P., *et al.* Distinct antibody responses to SARS-CoV-2 in children and  
696 adults across the COVID-19 clinical spectrum. *Nat Immunol* **22**, 25-31 (2021).
- 697 21. Monto, A.S., *et al.* Coronavirus Occurrence and Transmission Over 8 Years in the  
698 HIVE Cohort of Households in Michigan. *J Infect Dis* **222**, 9-16 (2020).
- 699 22. Shrock, E., *et al.* Viral epitope profiling of COVID-19 patients reveals cross-  
700 reactivity and correlates of severity. *Science* **370**(2020).
- 701 23. Ng, K.W., *et al.* Preexisting and de novo humoral immunity to SARS-CoV-2 in  
702 humans. *Science* (2020).
- 703 24. Edridge, A.W.D., *et al.* Seasonal coronavirus protective immunity is short-lasting.  
704 *Nat Med* **26**, 1691-1693 (2020).
- 705 25. Chan, J.F., *et al.* Genomic characterization of the 2019 novel human-pathogenic  
706 coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.  
707 *Emerg Microbes Infect* **9**, 221-236 (2020).
- 708 26. Haddad Natalie S , N.D.C., Kuruvilla Merin E, Morrison-Porter Andrea, Fagliha  
709 Anam, Kevin S Cashman, Richard P Ramonell, Shuya Kyu, Ankur Singh Saini,  
710 Monica Cabrera-Mora, Andrew Derrico, David Alter, John D Roback, Michael  
711 Horwath, James B O'Keefe, Henry M Wu, An-Kwok Ian Wong, Alexandra W  
712 Dretler, Ria Gripaldo, Andrea N Lane, Hao Wu, Saeyun Lee, Mindy Hernandez,  
713 Vanessa Engineer, John Varghese, Sang Le, Iñaki Sanz, John L Daiss, F Eun-  
714 Hyung Lee. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early  
715 COVID-19 Infection. *bioRxiv* (2020).
- 716 27. Katzelnick, L.C., *et al.* Antibody-dependent enhancement of severe dengue  
717 disease in humans. *Science* **358**, 929-932 (2017).
- 718 28. Guthmiller, J.J., Wilson P. C. Remembering seasonal coronaviruses. *Science* **370**,  
719 1272-1273 (2020).
- 720 29. Le Bert, N., *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and  
721 SARS, and uninfected controls. *Nature* **584**, 457-462 (2020).
- 722 30. Galani, I.E., *et al.* Untuned antiviral immunity in COVID-19 revealed by temporal  
723 type I/III interferon patterns and flu comparison. *Nat Immunol* (2020).
- 724 31. Wang, E.Y., Mao, T., Klein, J. , Dai, Y. , Huck, J. D., Liu, F., Zheng, N. S., Ting  
725 Zhou, Benjamin Israelow, Patrick Wong, Carolina Lucas, Julio Silva., *et al.* Diverse  
726 Functional Autoantibodies in Patients with COVID-19. *MedRxiv* (2020).
- 727 32. Glowinska-Olszewska, B., *et al.* Increasing Co-occurrence of Additional  
728 Autoimmune Disorders at Diabetes Type 1 Onset Among Children and  
729 Adolescents Diagnosed in Years 2010-2018-Single-Center Study. *Front*  
730 *Endocrinol (Lausanne)* **11**, 476 (2020).
- 731 33. Rodda, L.B., *et al.* Functional SARS-CoV-2-Specific Immune Memory Persists  
732 after Mild COVID-19. *Cell* (2020).
- 733 34. Young, B.E., *et al.* Effects of a major deletion in the SARS-CoV-2 genome on the  
734 severity of infection and the inflammatory response: an observational cohort study.  
735 *Lancet* **396**, 603-611 (2020).

- 736 35. Lam, J.Y., *et al.* Loss of orf3b in the circulating SARS-CoV-2 strains. *Emerg*  
737 *Microbes Infect*, 1-678 (2020).
- 738 36. Wu, F., *et al.* A new coronavirus associated with human respiratory disease in  
739 China. *Nature* **579**, 265-269 (2020).
- 740 37. Burbelo, P.D., Ching, K.H., Klimavicz, C.M. & Iadarola, M.J. Antibody profiling by  
741 Luciferase Immunoprecipitation Systems (LIPS). *J Vis Exp (JoVE)* **32**(2009).
- 742 38. Roweis, S. EM Algorithms for PCA and Sensible PCA. (1997).
- 743 39. Stacklies W., Redestig H., Scholz M., Walther D. & J., S. Methods – a  
744 Bioconductor package providing PCA methods for incomplete data.  
745 (Bioinformatics, 2007).  
746 <https://bioconductor.org/packages/release/bioc/html/pcaMethods.html>.
- 747 40. Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate  
748 Analysis. (2008). <http://www.jstatsoft.org/v25/i01/>
- 749 41. R project. <https://cran.rproject.org/web/packages/factoextra/index.html>




750

**Table 1. Subject cohorts details**




		<i>Pediatric COVID-19</i>		<i>Adults COVID-19</i>		<i>Negative</i>	
		N (%)		N (%)		N (%)	
<b>Patients</b>	<i>Samples</i>	254		36		33	
	<i>Individuals</i>	122		36		33	
<b>Symptoms</b>	<i>Asymptomatic</i>	44 (36%)		9 (25%)		-	
	<i>Mild/Severe</i>	78/0		25/1		-	
<b>Age</b>	Mean±stdev	10.8 ± 4.9 years	Mean±stdev	34 ± 17.1 years	Mean±stdev	29.3 ± 16.3 years	
		0-8 years 45 (37%)	Min	18	(N=13)	30 - 65	
		8-12 years 33 (27%)	Max	71	Pediatrics (N=20)	11 - 18	
		12-18 years 44 (36%)					
<b>Gender</b>	<i>Female</i>	49 (40%)		10 (28%)		17 (51%)	
	<i>Male</i>	73 (60%)		26 (72%)		16 (49%)	

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.03.21249180>; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.


**Spike  
Subunits**




**Other  
Structural  
proteins**



**Figure 1.**



**Figure 2.**



## Structural proteins

## Non-structural proteins






Figure 4.




**Figure 5.**






**Figure 6.**


**a**



**b**



**c**



**d**

